Stability Indicating RP-HPLC Method for Simultaneous Estimation of Lamivudine, Stavudine and Nevirapine in Pure and Tablet form

A new, simple, accurate, precise, reproducible, economical RP-HPLC method was developed for the simultaneous estimation of Lamivudine, Stavudine and Nevirapine in pure and pharmaceutical dosage form. A Phenomenex Gemini C6 Phenyl column (250mm × 4.6mm, 5µ) forms the stationary phase in isocratic mod...

Full description

Saved in:
Bibliographic Details
Published in:Research journal of pharmacy and technology 2022-02, Vol.15 (2), p.541-545
Main Authors: Patro, S.K., Prusty, A.K.
Format: Article
Language:English
Subjects:
Antiretroviral drugs
Calibration
Chromatography
Drug dosages
Enzymes
Hepatitis B
HIV
Human immunodeficiency virus
Ions
Laboratories
Membrane filters
Retention
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A new, simple, accurate, precise, reproducible, economical RP-HPLC method was developed for the simultaneous estimation of Lamivudine, Stavudine and Nevirapine in pure and pharmaceutical dosage form. A Phenomenex Gemini C6 Phenyl column (250mm × 4.6mm, 5µ) forms the stationary phase in isocratic mode, with the mobile phase consisting of 0.02 M Ammonium dihydrogen phosphate buffer having pH 2.5, adjusted with formic acid (98%). Buffer and methanol were used in the ratio of (50:50) to obtain well-resolved peaks of Lamivudine, Stavudine and Nevirapine from the combined dosage form. The flow rate and run time were set at 1 ml/min and 30 minutes respectively. The effluent was monitored at 264nm. The retention times for Lamivudine, Stavudine and Nevirapine were 2.837, 3.590, and 8.037 min respectively. The linearity for lamivudine, Stavudine and Nevirapine were in the range of 12-84, 24-160 and 16-112μg/ml respectively. The method was validated as per ICH guidelines Q 2B.
ISSN:0974-3618
0974-360X
0974-306X
DOI:10.52711/0974-360X.2022.00087